MaPLe: a study looking at the genes in follicular and diffuse large B cell lymphomas

There are no treatments in this study. The researchers need blood and tumour tissue samples for research.


Purpose of study

The aim of this research study is to find out more about gene changes in follicular and diffuse large B-cell lymphomas and to test if this information is helpful in choosing treatment.

The researchers take blood and tumour tissue samples (surplus material from biopsies you had already) from participants and check these for a range of genetic changes (molecular profiling).

They also want to collect information about the treatment participants have and how well this works. By checking this against the molecular profile, they may be able to help identify the best way for doctors to make treatment choices in these types of lymphoma.


What is involved

The research team ask for tissue from a sample of your lymphoma biopsy done either when you were first diagnosed or when the lymphoma came back later. They also ask for a blood sample. They use these samples to create your molecular profile. The molecular profile from your samples is then sent to your doctor, who may be able to use it to choose treatments most suitable for you.

The research team will also ask to keep a sample of your lymphoma to use for future research. You can still take part in the trial even if you refuse permission for this.


Who can enter

Your consultant can give you advice on whether this study might be suitable for you.

Around 3000 people are needed for this study.

You may be able to enter if:

  • You have been diagnosed with (or are having tests for) diffuse large B cell lymphoma OR follicular lymphoma ( grade 3B follicular lymphoma only).
  • Your doctor thinks you may be able to have a targeted drug for your lymphoma.
  • There is tissue available from a biopsy of your lymphoma taken either at diagnosis or when the lymphoma came back.

You will not be able to enter if:

  • You have any other type of lymphoma.

Further information

More information about this trial is available at Cancer Research UK.